Treatment of chronic viral hepatitis B/D and of acute and chronic viral hepatitis C - Consensus Report of the German Society of Gastroenterology and Metabolism;Behandlung der chronischen Virushepatitis B/D und der akuten und chronischen Virushepatitis C. Konsensus der Deutschen Gesellschaft fur Verdauungs- und Stoffwechselkrankheiten

Zeitschrift fur Gastroenterologie

Volumn 35, Issue 11, 1997, Pages 971-986

  Hopf, U ^a   Niederau, C ^a   Kleber, G ^a   Fleig, W E ^a  

^a Deutschen Gesell F Verdauungs /S ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; RIBAVIRIN; VIRUS ANTIBODY;

CHRONIC HEPATITIS; CONFERENCE PAPER; DRUG CONTRAINDICATION; DRUG EFFICACY; FEVER; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; INTRAVENOUS DRUG ADMINISTRATION; LIVER CIRRHOSIS; MUSCLE CRAMP; PATIENT COMPLIANCE; POLYNEUROPATHY; SUBCUTANEOUS DRUG ADMINISTRATION; VIRUS HEPATITIS;

ACUTE DISEASE; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIVIRAL AGENTS; CHRONIC DISEASE; GASTROENTEROLOGY; GERMANY; HEPATITIS B; HEPATITIS C; HEPATITIS C, CHRONIC; HEPATITIS D; HIV-1; HUMANS; INTERFERON-ALPHA; PROGNOSIS; SOCIETIES, MEDICAL;

EID: 0030670267     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (104)

1. Seibmann HK. Kriterien für die Beurteilung von Konsensuskonferenzcn in der Medizin. Fortschr Med 1992; 110: 35-6
2. Hoofnagle JH, Peters M, Mullen KD et al. Randomized, controlled trial of recombinant human alphainterferon in patients with chronic hepatitis B. Gastroenterology 1988; 95: 1318-25
3. Brook MG, McDonald JA, Karayiannis P et al. Randomized controlled trial of Interferon alfa 2a (rbe) (Roferon-A) for the treatment of chronic hepatitis B virus (HBV) infection: Factors that influence response. Gut 1989; 30: 1116-22
4. Perrillo RP, Schiff ER, Davis GL et al. A randomized, controlled trial of interferon alfa-2b and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med 1990; 323: 295-301
5. Perrillo RP. Antiviral therapy of chronic hepatitis B: Past, present, and future. J Hepatol 1993; 17: 56-63
6. Korenman J, Baker B, Waggoner J et al. Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med 1991; 114: 629-34
7. Carreño V, Castillo I, Molina J, Porres JC, Bartolome J. Long-term follow-up of hepatitis B chronic carriers who responded to interferon therapy. J Hepatol 1992; 15: 102-6
8. Lok ASF, Hau-Tim C, Lin VWS, Ma OCK. Long-term follow-up of chronic hepatitis B patients treated with interferon alfa. Gastroenterology 1993; 105: 1833-8
9. Perrillo RP, Brunt EM. Hepatic histologic and immunohistochemical changes in chronic hepatitis B after prolonged clearance of hepatitis B e antigen and hepatitis B surface antigen. Ann Intern Med 1991; 115: 113-5
10. Niederau C, Heintges T, Niederau M, Stremmel W, Strohmeyer G. Prospective randomized controlled trial of sequential treatment with corticoids and (α-interleron versus treatment with interferon alone in patients with chronic active hepatitis B. Eur J Med 1992; 1: 396-402
11. Niederau C, Heintges T, Lange S et al. Long-term follow-up of HBeAg patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996; 334: 1422-7
12. Hoofnagle JH, Lau D. Chronic viral hepatitis - benefits of current therapies. N Engl J Med 1996; 22: 1470-1
13. Sherlock DE. The management of chronic hepatitis. Curr Opin Gastroenterol 1996; 12: 217-23
14. Sherlock DS. Management of acute and chronic hepatitis due to hepatitis B virus or hepatitis C virus. Curr Opin Gastroenterol 1995; 11: 188-94
15. Wong DK, Cheung AM. O'Rourke et al. Effect of alpha interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: A metaanalysis. Ann Intern Med 1993; 119: 312-23
16. Tine F, Liberati A, Craxi A, Almasio P, Pagliaro L. Interferon treatment in patients with chronic hepatitis B: A meta-analysis of the published literature. J Hepatol 1993; 18: 154-62
17. Scullard GH, Andres LL. Greenherg HB et al. Antiviral treatment of chronic hepatitis B virus infection: Improvement in liver disease with interferon and adenine arabinoside. Hepatology 1981; 5: 228-32
18. Garcia G, Smith CI, Weissberg JI et al. Adenine arabinoside monophosphate (vidarabine phosphate) in combination with human leukocyte interferon in the treatment of chronic hepatitis B: A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1987; 107: 278-85
19. Alexander GJM, Brahm J, Fagan EA et al. Controlled clinical trial of acyclovir in chronic hepatitis B virus infection. J Med Virol 1987; 21: 81-7
20. Fried MW, Korenman JC, DiBisceglie AM et al. A pilot study of 2′,3′-dideoxyinosine for the treatment of chronic hepatitis B. Hepatology 1992; 16: 861-4
21. Janssen HLA, Berk L, Heitjink RA, ten Kate FJW, Schalm SW. Interferon-alpha and zidovudine combination therapy for chronic hepatitis B: Results of a randomized, placebo-controlled trial. Hepatology 1993; 17: 383-8
22. Fried MW, Fong T-L, Swain MG et al. Therapy of chronic hepatitis B with a 6-month course of ribavirin. J Hepatol 1994; 21: 145-50
23. McKenzie R, Fried MW, Sallie R et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med 1995; 333: 1099-105
24. Dienstag JL, Perillo RP, Schiff EF et al. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995; 333: 1657-61
25. Dienstag JL, Schiff ER, Mitchell M et al. Extended lamivudine retreatment for chronic hepatitis B. Hepatology 1996; 24: A188
26. Benner KG, Rosen HR, Flora KD. Famciclovir treatment of decompensated HBV cirrhosis. Hepatology 1996; 24: A282
27. Trepo C, Jezek P, Atkinson GF, Boon RJ. Efficacy of Famciclovir in chronic hepatitis B: Results of a dose finding study. Hepatology 1996; 24: A247
28. Ben-AriZ, Shmueli D, Mor E et al. Beneficial effect of lamivudine in recurrent hepatitis B post liver transplantation. Hepatology 1996; 24: A482
29. Grellier L, Mutimer D, Ahmed M et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996; 348: 1212-5
30. Markowitz J, Pakrasi A, Hollis P et al. Efficacy of lamivudine for prophylaxis arid treatment of hepatitis B in liver transplant patients. Hepatology 1996; 24: A182
31. Perillo R, Rakela J, Martin P et al. Lamivudine for hepatitis B after liver transplantation (OLT). Hepatology 1996; 24: A82
32. Kruger M, Tillmann C, Trautwein K et al. Famciclovir treatment of hepatitis B virus recurrence after orthotopic liver transplantation - a pilot study. Hepatology 1995; 22: A449
33. Prieto M, Cordoba J, Berenguer M et al. Famciclovir treatment of hepatitis B virus (HBV) infection alter liver transplantation. Hepatology 1996; 24: A419
34. Rabinovitz M, Dodson F, Rakela J, Famciclovir for recurrent hepatitis B (HBV) infection after liver transplantation (OLTX). Hepatology 1996; 24: A282
35. Drews D, Strum E, Burdelski M. Two cases of de novo hepatitis B (HBV) infection in pedriatic patients following orthotopic liver transplantation (OLT): Successful treatment with famciclovir. Hepatology 1996; 24: A504
36. Fischer KP, Cheng Y-C, Tyrrell DJL. The mutation in duck hepatitis B virus polymerase which confers resistance to lamivudine (Beta-L-[-Thiacytidine; 3TC]) also confers cross-resistance to beta-L-dideoxy-5-fluorocytidine(FddC). Hepatology 1996; 24: A188
37. Gutfreund KS, Fischer KP, Tippies G et al. Late breakthrough of HBV viremia with lamivudine as a single agent for prevention of graft reinfection in liver transplantation for cirrhosis secondary to hepatitis B. Hepatology 1996; 24: A285
38. Aye TT, Bartholomeusz AI. Shaw T et al. Hepatitis B virus polymerase mutations during famciclovir therapy in patients following liver transplantation. Hepatology 1996; 24: A285
39. Naoumov NV, Chokchi S, Smith HM et al. Emergence and characterization of lamivudine-resistant hepatitis B virus variant. Hepatology 1996; 24: A282
40. Gregorio GV, Jara P, Hierro L et al. Lymphoblastoid interferon alfa with or without steroid pretreatment in children with chronic hepatitis B: A multicenter controlled trial. Hepatology 1996; 23: 700-7
41. Ryff JP. The judicious use of interferon-α-2a for the treatment of chronic hepatitis B. J Hepatol 1993; 17: 42-6
42. Brook MG, Chan G, Yap I et al. Randomized controlled trial of lymphoblastoid interferon alfa in Europid men with chronic hepatitis B virus infection. Br Med J 1989; 299: 652-9
43. Niederau C, Niederau M, Stremmel W, Strohmeyer G. Therapie der chronischen Hepatitis B mit alfa-Interferon: Selektion der Patienten. In: Paumgartner G, Strohmeyer G (eds.). Chronische Virushepatitis und ihre Behandlung mit Interferon alfa. Springer Verlag. Berlin, Heidelberg, New York 1991: 35-45
44. Zarski JP, Causse X, Cohard M et al. A randomized, controlled trial of interferon alfa-2b alone and with simultaneous prednisone for the treatment of chronic hepatitis B. French Multicenter Group. J Hepatol 1994; 20: 735-41
45. Thomas HC, Lok AS, Carreno V et al. Comparative Study of three doses of interferon-alpha in chronic active hepatitis B. The International Hepatitis Gropup. J viral Hepat 1994; 1: 139-8
46. Hoofnagle JH, DiBisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997; 336: 347-56
47. Brunetto MR, Oliveii F, Rocca G et al. Natural course and response to interferon occhronic hepatitis B accompanied by antibody to hepatitis B antigen. Hepatology 1989; 10: 198-202
48. Brunetto MR, Giarin M, Saracco G et al. Hepatitis B unable to secrete e antigen and response to interferon in chronic hepatitis B. Gastroenterology 1993; 105: 845-50
49. Pastore G, Santantonio T, Milella M et al. Anti-HBe-positive chronic hepatitis B with HBV-DANN in the serum response to a six-months course of lymphoblastoid interferon. 1992; 14: 221-5
50. Erhardt A, Heintges T, Hensel F et al. Chronic hepatitis B negative for HABe-Antigen: Clinical aspects and response to Interferon (IFN) in a non-endemic area. Hepatology 1996; 24: 619
51. Fattovich G, Farci P, Rugge M et al. A randomized controlled trial of lymphoblastoid interferon-alpha in patients with chronic hepatitis B lacking HbeAg. Hepatology 1992; 15: 584-9
52. Niederau C, Heintges T, Niederau M et al. Auswahl der Patienten mit chronischer Hepatitis B für eine Therapie mit Alpha-Interferon. Z ärztl Fortbld 1993; 87: 273-8
53. Rosina, F, Pintus, C, Meschievitz C, Rizetto M. A randomized controlled trial of a 12-month course of recombinant human interferon-alfa in chronic delta (type D) hepatitis: A multicenter Italian study. Hepatology 1991; 13: 1052-6
54. Rosina F, Cozzolongo R. Interferon in HDV infection. Antiviral Res 1994; 24: 165-74
55. Farci P, Mandas A, Coiana A, Lai ME et al. Treatment of chronic hepatitis D with interferon-alfa 2a. N Engl J Med 1994; 330: 88-94
56. Perillo RP, Chronic hepatitis B. problem patients (including patients with decompensated disease). J Hepatol 1995; 22: 45-8
57. Heintges T, Niederau C, Strohmeyer G. Diagnostik und Therapie der autoimmunen Hepatitis. Z Gastroenterol 1995; 33: 426-37
58. Heintges T, Niederau C, Hensel F, Häussinger D. Diagnose und Therapie der chronischen Virushepatitis. Z Gastroenterol 1996; 34: 446-56
59. Heintges T, Niederau C, Goertz G, Strohmeyer G. Interferon treatment causes deterioration of lichen ruber planus but not of acute intermittent porphyria. J Hepatol 1994; 20: 1151-3
60. Muller R, Samuel D, Fassatti LR et al. »Eurohep« consensus report on the management of liver Transplantation for hepatitis B virus infection. J Hepatol 1994; 21: 1140-3
61. Aguet M, Blanchard B. High affinity binding of 125J-Iabeled mouse Interferon to a special cell surface receptor: II. Analysis of binding properties. Virology 1981; 115: 249-61
62. Hwang SJ, Lee SD, Chan CY, Lu RH, Lo KJ. A randomized controlled trial of recombinant interferon alpha-2b in the treatment of Chinese patients with acute posttransfusion hepatitis C. J Hepatol 1994; 21: 831-6
63. Lampertico P, Rumi M, Romeo R et al. Multicenter randomized controlled trial of recombinant interferon alpha 2b in patients with acute transfusion associated hepatitis. Hepatology 1994: 19; 19-22
64. Omata M, Yokosuka O, Takano S et al. Resolution of acute hepatitis C after therapy with natural beta interferon. Lancet 1991; 338: 914-5
65. Takano S, Satomura Y, Omata M. Effects of interferon beta on non-A, non-B acute hepatitis. A prospective, randomized, controlled-dose study. Gastroenterology 1994; 107: 805-11
66. Viladomiu L, Genesca J, Esteban JL et al. Interferon-α in acute posttransfusion hepatitis C: A randomized, controlled trial. Hepatology 1992; 15: 767-9
67. Camma C, Almasio P, Craxi A. Interferon treatment for acute hepatitis C. A meta-analysis. Dig Dis Sci 1996; 41: 1248-55
68. Nishigunchi S, Kuroki T, Nakatani S et al. Randomised trial of the effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C. Lancet 1995; 346: 1051-5
69. Mazzella G, Accogli E, Sottili S et al. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol. 1996; 24: 141-7
70. Fattovieh G, Giustina G. Degos F et al., and the European Concerted Action on Viral Hepatitis (EURO-HEP). Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. J Hepatol 1997; 27: 201-5
71. Bruno S, Silini E, Crosignani A et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: A prospective study. Hepatology 1997; 25: 754-8
72. Heller J, Musiolik J, Homrighausen K, Sauerbruch T, Spengler U. Vorkommen und Bedeutung von Autoantikörpern in Rahmen der Interferontherapie der chronischen hepatitis C. Dtsch Med Wochenschr 1996; 212: 1179-83
73. Okanoue T, Sakamoto S. Itoh Y et al. Side effects of high dose interferon therapy for chronic hepatitis C. J Hepatol 1996; 25: 283
74. Berg T, König V, Küther S et al. Prognostische Relevanz der Hepatitis-C-Virus-Genotypen für das Ansprechen auf Interferon-alpha. Z Gastroenterol 1995; 33: 426-30
75. Hanley JP, Jarvis LM, Andrew J et al. Interferon treatment for chronic hepatitis C infection in hemophiliacs-influence of virus load, genotype, and liver pathology on response. Blood 1996; 87: 1704-9
76. Hopf U, Berg T, König V et al. Treatment of chronic hepatitis C with interferon alfa, long-term follow-up and prognostic parameters. J Hepatol 1996; 24 (2 suppl.): 67-73
77. Orito E, Mizokami M, Nakano M et al. Serum hepatitis C virus RNA level as a predictor of subsequent response to interferon-alfa therapy in Japanese patients with chronic hepatitis C. J Med Virol 1994; 44: 410-4
78. Roffi L, Mels GC, Antonelli et al. Breakthrough during recombinant interferon alfa therapy in patients with chronic hepatitis C virus infection: Prevalence, etiology, and management. Hepatology 1995; 21: 645-9
79. Vento S, Concia E, Ferraro T. Lack of sustained efficacy of interferon in patients with chronic hepatitis C. N Engl J Med 1996; 334: 1479-80
80. DeAlva E, Camps J, Pardo-Midán J et al. Histological outcome of chronic hepatitis C treated with a 12-months course of lymphoblastoid alfa interferon. Liver 1993; 13: 73-9
81. Chemello L, Bonetti P, Cavaletto L et al., and the Tri Veneto Viral Hepatitis Group. Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. Hepatology 1995; 22: 700-6
82. Hiramatsu N, Hayashi H, Kasahara A et al. Improvement of liver fibrosis in chronic hepatitis C patients treated with natural Interferon alpha. J Hepatol 1995; 22: 135-42
83. Lin R, Roach E, Zimmermann M, Strasser S, Farrell G. Interferon-alfa-2b for chronic hepatitis C: Effects of dose increment and duration of treatment on response rates. Results of the first multicenter Australian trial. Australia Hepatitis C Study Group. J Hepatol 1995; 23: 487-96
84. Poynard T, Bedossa P, Chevallier M et al. and the Multicenter Study Group. A comparison of three Interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med 1995; 332: 1457-62
85. Benhamou JP, Hopf U, Rizzetto M et al. Spacey B and Non-A, non-B (C) Study Group. Long-term lymphoblastoid interferon enhances sustained responses and improves histological activity up to twelve months post-treatment. Hepatology 1995; 22: A151.
86. Davis J. Prediction of response to interferon treatment of chronic hepatitis C. J Hepatol 1994; 21: 1
87. Kasahara A, Hayashi N, Hiramatsu et al. Ability of prolonged interferon treatment to supress relapse after cessation of therapy in patients with chronic hepatitis C: A multicenter randomized controlled trial. Hepatology 1995; 21: 291-7
88. Niederau C, Heintges T, Häussinger D. Treatment of hepatitis C with α-interferon: An analysis of the literature. Hepatogastroenterology (1996), im Druck.
89. Reichard O, Foberg U, Frydön A et al. High sustained response rate and clearence of viremia in chronic hepatitis C after treatment with interferon-CC2 b for 60 weeks. Hepatology 1994; 19: 280-5
90. Shindo M, Arai K, Sokawa Y, Okuno T. Hepatic hepatitis C virus RNA as a predictor of a long-term response to interferon-alpha therapy. Ann Intern Med 1995; 15: 586-91
91. Brouwer JT, Nevens F, Kleter GEM et al. Which hepatitis C patient will benefit from interferon? Multivariant analysis of 350 patients treated in a Benelux Multicentre Study. J Hepatol 1993; 18 (suppl. 1): S10
92. Van Thiel DH, Gavaler JS, Wright HI, Friedlander L. Responses to alfa interferon therapy are influenced by the iron content of liver. Gastroenterology 1992; A904
93. Yoshioka K, Kakumu S, Wakita et al. Detection of hepatitis C virus by polymerase chain reaction and response to interferon-α therapy: Relationship to genotypes of hepatitis C virus. Hepatology 1992; 16: 293-9
94. Weiland O, Schvarcz R, Westjal R, Norkrans G, Fryden A.Therapy of chronic post-transfusion non-A, non-B hepatitis with interferon alfa-2b: Swedish experience. J Hepatol 1990; 11 (suppl. 2): 57-62
95. Hagiwara H, Hayashi N, Mita N et al. Quantitative analysis of hepatitis C virus RNA in serum during Interferon alfa therapy. Gastroenterology 1993; 104: 877-83
96. Hino K, Sainokami S, Shimoda K et al. Genotypes and titers of hepatitis C virus for predicting response to interferon in patients with chronic hepatitis C. J Med Virol 1994; 42: 299-305
97. Hopf U, Küther S, König V et al. Langzeitbeobachtung der chronischen Hepatitis C nach Behandlung mit rekombinantem Interferon-alpha-2a. Z Gastroenterol 1994; 32: 425-30
98. Kanai K, Kako M, Okamoto H. HCV genotypes in chronic hepatitis-C and response to interferon. Lancet 1992; 339: 1543
99. Martinot-Peignoux M, Marcellin P. Pouteau P et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995; 22: 1050-6
100. Takada N, Takase S, Enomoto N, Takada A, Date T. Clinical backrounds of the patients having different types of hepatitis C virus genomes. J Hepatol 1992; 14: 35-40
101. Yoshioka K, Higashi Y. Yamada M et al. Predictive factors in the response to interferon therapy in chronic hepatitis C. Liver 1995; 15: 57-62
102. Enomoto N, Sakuma I, Asahina M et al. Mutations in the non-structural protein 5A gene and response to interferon in patients with chronic hepatitis C virus Ib infection. N Engl J Med 1996; 334: 77-81
103. Squadrito G, Leone F, Nalpas B et al. Absence of correlation between HCV NS5A mutations and response to alpha interferon in French patients with chranic hepatitis C. J Hepatol 1996; 25 (suppl. 1): 78
104. Zeuzem S, Lee H-J, Roth WK. Mutations in the non-structural 5A gene of European hepatitis C virus isolates and response to interferon-alpha. Hepatology 1997; 25: 740-4